Chronic Kidney Disease Market Emerging as a High-Growth Healthcare Investment Space Through 2036 - DelveInsight

The Chronic Kidney Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Kidney Disease pipeline products will significantly revolutionize the Chronic Kidney Disease market dynamics.

DelveInsight's "Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Chronic Kidney Disease, historical and forecasted epidemiology as well as the Chronic Kidney Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Chronic Kidney Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Kidney Disease Market Forecast
https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Chronic Kidney Disease Market Report:
* The Chronic Kidney Disease Market Size across the 7MM was valued at nearly USD 5 billion in 2025 and is anticipated to witness further growth through 2036.
* In January 2026, Mineralys Therapeutics reported a corporate update that highlighted recent and upcoming clinical and regulatory milestones for Lorundrostat in CKD and related conditions.
* In Sept 2025, eGenesis obtained FDA approval for its Investigational New Drug (IND) application to initiate clinical trials of EGEN-2784, a genetically engineered porcine kidney, for end-stage kidney disease (ESKD). The Phase 1/2/3 trial will assess safety and efficacy in dialysis-dependent patients aged 50 and above who are on the transplant waiting list.
* In August 2025, Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotech company specializing in kidney disease therapies, announced that the U.S. Patent and Trademark Office has issued U.S. Patent 12,377,082 for UNI-494 in the treatment of Chronic Kidney Disease (CKD). This patent extends a prior method-of-use patent that covered UNI-494 for treating Acute Kidney Injury.
* In March 2025, The FDA approved an expanded indication for furosemide injection (Furoscix; scPharmaceuticals, Inc.) to manage edema in adult patients with chronic kidney disease (CKD), including nephrotic syndrome. The expanded treatment is anticipated to be available by April 2025, following the FDA's acceptance of the supplemental new drug application in July 2024.
* In February 2025, semaglutide (Ozempic) has been approved by the U.S. Food and Drug Administration for patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes (T2D). This approval represents a significant milestone, as it is the first GLP-1 receptor agonist shown to lower the risk of kidney disease progression, kidney failure, and cardiovascular-related death in these patient populations.
* In February 2025, Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company leveraging human genetics to develop innovative small-molecule precision medicines for renal, cardiovascular, and metabolic diseases, has announced that the first patient has been dosed in its Phase 2 HORIZON Study of MZE829 for APOL1 kidney disease (AKD). MZE829 is an oral small-molecule APOL1 inhibitor being developed as a potential treatment for AKD, a form of chronic kidney disease that affects over one million patients in the United States.
* In November 2024, Unicycive Therapeutics (Nasdaq: UNCY) announced that the U.S. FDA has accepted its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC), with a target action date of June 28, 2025, under the PDUFA. If approved, OLC has the potential to significantly enhance the treatment of hyperphosphatemia in Chronic Kidney Disease patients undergoing dialysis.
* In July 2024, Renalys Pharma has raised ¥6 billion ($3.8 million) in a Series A funding round to advance clinical trials for kidney disease treatments across Asia. The financing was led by Catalys Pacific and SR One, with additional support from a group of investors, including JPS Growth Investment Limited Partnership, Sumitomo Mitsui Trust Bank, Japan Co-Invest IV Limited Partnership, and NVCC No.9 Investment Limited Partnership.
* The US accounts for the largest Chronic Kidney Disease Market Size i.e., nearly USD 2.9 Billion, in comparison to EU4 (Germany, Italy, France, and Spain) and the UK, and Japan.
* Among EU4 and the UK, Germany had the highest Chronic Kidney Disease Market Size at approximately USD 480 million in 2025, followed by the UK with around USD 335 million in the same year.
* The Chronic Kidney Disease Market Size in Japan was valued at approximately USD 665 million, capturing about 13% of the market size in 2025, which is expected to change by 2036.
* As per DelveInsight analysis, in 2025, there were approximately 82.5 million prevalent and nearly 14.5 million Chronic Kidney Disease Diagnosed Prevalent Cases in the 7MM. These cases are projected to increase further during the forecast period (2026-2036), due to the increasing geriatric population.
* In 2025, the US accounted for the highest number of Chronic Kidney Disease Diagnosed Prevalent Cases among the 7MM, representing approximately 26% of the total, with around 3.8 million cases. This figure is anticipated to rise by 2036.
* In 2025, Germany recorded the highest number of chronic kidney disease diagnosed prevalent cases among EU4 and the UK, with nearly 2.2 million cases, followed by the UK with approximately 2.1 million cases. In contrast, Italy reported the lowest, with around 845,000 cases.
* In 2025 Japan accounted for around 2.5 million Chronic Kidney Disease Diagnosed Prevalent Cases, which is expected to change by 2036.
* As per DelveInsight analysis, the gender distribution of the disease in the US indicates a female predominance, with approximately 2.1 million cases among females and 1.7 million cases among males in 2025.
* Key Chronic Kidney Disease Companies: Tricida, Otsuka Pharmaceuticals, AstraZeneca, and others
* Key Chronic Kidney Disease Therapies: TRC101 (Veverimer), Tolvaptan, AZD5718, and others
* The Chronic Kidney Disease epidemiology based on gender analyzed that Chronic Kidney Disease is slightly more common in women (14%) than men (12%)

Chronic Kidney Disease Overview
Chronic Kidney Disease (CKD) is a long-term condition characterized by a gradual loss of kidney function over time. The kidneys play a crucial role in filtering waste, toxins, and excess fluids from the blood. In CKD, this filtering ability is impaired, leading to a buildup of harmful substances in the body.
The condition is often caused by underlying health issues such as diabetes, high blood pressure, or glomerulonephritis. Symptoms may not appear until the disease is advanced and can include fatigue, swelling, nausea, and difficulty concentrating. Left untreated, CKD can progress to kidney failure, requiring dialysis or a kidney transplant. Early detection and management, including lifestyle changes and medications, can help slow disease progression.

Get a Free sample for the Chronic Kidney Disease Market Report:
https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Kidney Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Kidney Disease Epidemiology Segmentation:
The Chronic Kidney Disease market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:
* Total Prevalence of Chronic Kidney Disease
* Prevalent Cases of Chronic Kidney Disease by severity
* Gender-specific Prevalence of Chronic Kidney Disease
* Diagnosed Cases of Episodic and Chronic Chronic Kidney Disease

Download the report to understand which factors are driving Chronic Kidney Disease epidemiology trends @ Chronic Kidney Disease Epidemiology Forecast
https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Kidney Disease Epidemiology Segmentation:
The Chronic Kidney Disease market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:
* Total Prevalence of Chronic Kidney Disease
* Prevalent Cases of Chronic Kidney Disease by severity
* Gender-specific Prevalence of Chronic Kidney Disease
* Diagnosed Cases of Episodic and Chronic Chronic Kidney Disease

Chronic Kidney Disease Market
The dynamics of the Chronic Kidney Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2022-2036.
"Although the pipeline for the treatment of Chronic Kidney Disease looks robust, most of the investigational therapies aim at improving kidney function (measured by improved renal output), there are no curative therapies in development that aim to regain kidney function."

Chronic Kidney Disease Therapies and Key Companies
* TRC101 (Veverimer): Tricida
* Tolvaptan: Otsuka Pharmaceuticals
* AZD5718: AstraZeneca

To know more about Chronic Kidney Disease treatment, visit @ Chronic Kidney Disease Medications
https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Kidney Disease Market Drivers
* Rising Prevalence of CKD
* Advancements in Diagnostic Tools
* Development of Novel Therapies
* Increased Healthcare Spending
* Awareness Campaigns
* Favorable Regulatory Approvals

Chronic Kidney Disease Market Barriers
* High Treatment Costs
* Limited Access to Healthcare
* Late Diagnosis
* Side Effects of Therapies
* Regulatory Hurdles
* Patient Adherence Issues

Scope of the Chronic Kidney Disease Market Report
* Study Period: 2022-2036
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Chronic Kidney Disease Companies: Tricida, Otsuka Pharmaceuticals, AstraZeneca, and others
* Key Chronic Kidney Disease Therapies: TRC101 (Veverimer), Tolvaptan, AZD5718, and others
* Chronic Kidney Disease Therapeutic Assessment: Chronic Kidney Disease current marketed and Chronic Kidney Disease emerging therapies
* Chronic Kidney Disease Market Dynamics: Chronic Kidney Disease market drivers and Chronic Kidney Disease market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Chronic Kidney Disease Unmet Needs, KOL's views, Analyst's views, Chronic Kidney Disease Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.